Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer

NCT01491204 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.

NCT NCT01491204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01491204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer
Lead sponsor
Hanmi Pharmaceutical Company Limited
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2006
Completion date
October 31, 2008
Enrollment
25 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors